RecruitingEarly Phase 1NCT04449198

Type 1 Diabetes, Endothelin, and Skeletal Muscle Mitochondrial Dysfunction: The Role of Sirtuin-1


Sponsor

Augusta University

Enrollment

24 participants

Start Date

Oct 14, 2020

Study Type

INTERVENTIONAL

Conditions

Summary

The proposed study is designed to test the hypothesis that treatment of resveratrol for 12 weeks will improve both endothelin-B receptor (aim 1) and skeletal muscle mitochondrial function (aim 2) in people with type 1 diabetes.


Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This study is investigating whether problems with blood vessel function (specifically a molecule called endothelin) contribute to poor muscle energy production in people with Type 1 diabetes. **You may be eligible if...** - You are a man or premenopausal woman - You have been diagnosed with Type 1 diabetes (insulin-dependent) - You are otherwise in good general health **You may NOT be eligible if...** - You have liver, heart, or kidney disease - Your diabetes is poorly controlled (HbA1c above 12%) - You have diabetes complications such as nerve damage (neuropathy) - You have uncontrolled high blood pressure - You are currently a smoker Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGResveratrol

500 mg of oral trans-resveratrol twice daily (in the morning and evening) for 12-weeks

OTHERPlacebo

placebo for 12 weeks


Locations(1)

Augusta University/Georgia Prevention Institute/ Laboratory of Integrative and Exercise Physiology

Augusta, Georgia, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT04449198


Related Trials